Medical Condition News

RSS
Genetic markers could help predict heart attack in patients with heart disease

Genetic markers could help predict heart attack in patients with heart disease

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Righttime Medical Care CEO presents lecture on MTBI at Maryland’s annual conference

Righttime Medical Care CEO presents lecture on MTBI at Maryland’s annual conference

Diabetic Ketoacidosis is disproportionately high among youth

Diabetic Ketoacidosis is disproportionately high among youth

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

Researchers quantify proportion of adults potentially affected by updated 2014 BP recommendations

Researchers quantify proportion of adults potentially affected by updated 2014 BP recommendations

International scientists identify novel genetic defects that induce oesophageal cancer

International scientists identify novel genetic defects that induce oesophageal cancer

Cheap drug holds promise of treating heart attack patients

Cheap drug holds promise of treating heart attack patients

Newly identified protein markers have potential to contribute to better understanding of heart disease

Newly identified protein markers have potential to contribute to better understanding of heart disease

MADIT-CRT study: Boston Scientific CRT defibrillator reduces risk of death in mild heart failure patients

MADIT-CRT study: Boston Scientific CRT defibrillator reduces risk of death in mild heart failure patients

New gene-editing system holds potential for treating many genetic disorders

New gene-editing system holds potential for treating many genetic disorders

Study on effects of cholesterol-lowering medications on sexual health

Study on effects of cholesterol-lowering medications on sexual health

Setting clocks ahead 1 hour may accelerate cardiac events in some, shows study

Setting clocks ahead 1 hour may accelerate cardiac events in some, shows study

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Millions of US adults may no longer need blood pressure medication, study suggests

Millions of US adults may no longer need blood pressure medication, study suggests

Studies reveal role of spiritual care in treating people facing serious illnesses

Studies reveal role of spiritual care in treating people facing serious illnesses

Study of astronauts show heart becomes more spherical when exposed to microgravity in space

Study of astronauts show heart becomes more spherical when exposed to microgravity in space

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.